{"id":"202204277763","sourceId":"dow-jones","sourceName":"Global News Select","providerName":"Dow Jones","title":"Zentalis Pharmaceuticals Sells Shares to Pfizer for $25 Million","publishedDate":"2022-04-27T06:39:00-05:00","body":[{"type":"p","contentObject":[{"type":"text","content":"\n  By Chris Wack ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"pre","contentObject":[{"type":"text","content":"\n ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  Zentalis Pharmaceuticals Inc. said it selling 954,000 common shares at $26.21 a share to Pfizer Inc. for proceeds of $25 million. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  The biopharmaceutical company said the common shares were offered and sold to Pfizer in a registered direct offering conducted without an underwriter or placement agent. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  The offering is expected to close on or about Wednesday. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  Zentalis said it intends to use the proceeds to help fund ongoing and planned clinical trials, including studies of ZN-c3, its Wee1 inhibitor, and ZN-d5, its BCL-2 inhibitor, and for working capital and general corporate purposes. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  With prioritization of the clinical development of ZN-c3 and ZN-d5, budget reallocation and Pfizer's investment, the company said it is extending its current cash runway into the first quarter of 2024. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  Pfizer also expects to help Zentalis enhance its clinical development program. The companies have agreed to collaborate to advance the clinical development of ZN-c3. Zentalis will maintain full economic ownership and control of ZN-c3 and the rest of its pipeline. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  Zentalis shares were up 12% to $24.36 in premarket trading. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"pre","contentObject":[{"type":"text","content":"\n ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  Write to Chris Wack at chris.wack@wsj.com ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"pre","contentObject":[{"type":"text","content":"\n ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  (END) Dow Jones Newswires","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  April 27, 2022 07:39 ET (11:39 GMT)","gated":false}],"gated":false},{"type":"text","content":"\n\nCopyright (c) 2022 Dow Jones & Company, Inc.","gated":false}]}